EVAXION BIOTECH
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections.
EVAXION BIOTECH
Social Links:
Industry:
Biotechnology
Founded:
2008-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.evaxion-biotech.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
57 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Google Maps Pound Sterling New Relic
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
ProtActivity
ProtActivity focusses on the development of vaccines against protozoal diseases.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Employees Featured
Founder
Stock Details
Investors List
Lincoln Park Capital Fund
Lincoln Park Capital Fund investment in Post-IPO Equity - Evaxion Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer |
Official Site Inspections
http://www.evaxion-biotech.com Semrush global rank: 6.69 M Semrush visits lastest month: 867
- Host name: dedi5059.your-server.de
- IP address: 136.243.123.133
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Evaxion Biotech"
Evaxion Biotech - Crunchbase Company Profile
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company …See details»
Evaxion A/S - LinkedIn
Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial …See details»
Press Releases | Evaxion
The Investor Relations website contains information about Evaxion's business for stockholders, potential investors, and financial analysts.See details»
Evaxion Biotech Company Profile - Office Locations, Competitors
Oct 29, 2024 Evaxion Biotech has 5 employees at their 1 location and $507 k in annual revenue in FY 2023. See insights on Evaxion Biotech including office locations, competitors, revenue, …See details»
Evaxion Biotech - Org Chart, Teams, Culture & Jobs | The Org
View Evaxion Biotech's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Evaxion Biotech - Company info. interviews, news
Jan 26, 2024 Evaxion Biotech Uses AI To Develop Anticancer And Antimicrobial Vaccines Aug. 21, 2017 This is an interview with Niels Iversen Møller, a CEO, and Co-founder of Evaxion …See details»
Evaxion Biotech Company Profile: Funding, Investors & Partnerships
We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to …See details»
Leading AI-Driven Vaccine Development - Evaxion Biotech
Learn how Evaxion leverages AI in vaccine development, and discover our mission, advanced technology, and leadership team committed to improving patient outcomes.See details»
Mission, Vision & Core Values of Evaxion Biotech
Oct 2, 2024 Evaxion Biotech's mission, vision, and core values play a crucial role in shaping the company's success in the field of vaccine discovery and development. These elements …See details»
Evaxion significantly expands vaccine development collaboration …
Sep 26, 2024 Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power …See details»
Evaxion Biotech - businessabc.net
Feb 25, 2025 Evaxion Biotech was founded in 2015 by scientists Sven Hanson and Jenny Nordvall. With the help of a team of experienced researchers, we have continued to …See details»
Evaxion Biotech - Funding, Financials, Valuation & Investors
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.See details»
Evaxion announces business update and first quarter 2025
12 hours ago COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ …See details»
Evaxion to present new phase 2 data for AI-designed personalized …
COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered …See details»
Evaxion Biotech | Evaxion Biotech
Jan 20, 2025 Are you eager to deep-dive into Evaxion's business? Download our company presentation below.See details»
Evaxion Biotech - Contacts, Employees, Board Members
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.See details»
Evaxion Partners With Pharmaceutical Company Afrigen
Sep 20, 2023 Evaxion Biotech A/S is a clinical-stage biotech company developing world-leading AI platforms. Evaxion's proprietary and scalable technologies harness the power of artificial …See details»
Pipeline - Evaxion’s world-class product candidates | Evaxion Biotech
Discover Evaxion's dynamic development pipeline showcasing pioneering AI-driven vaccines for oncology and infectious diseases.See details»
Evaxion A/S Reports Progress on EVX-01 and First Quarter 2025
Mar 31, 2025 Evaxion A/S specializes in developing AI-Immunology™ powered vaccines, focusing on clinical-stage biotech solutions for cancer and infectious diseases. What …See details»
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025
2 days ago Evaxion aims for at least 2 new deals in 2025 and is, in the meantime, further developing its AI platform to stay ahead of competition. Read why EVAX is a Buy.See details»